MedinCell Enters Into a Technology Agreement for Long-Acting Injectable Products

MedinCell announced today that it has entered into a non-exclusive collaboration agreement with Sandoz, a Novartis company.
According to the company press release:

Both parties will join forces to develop and commercialize long-acting injectables with a primary focus on oncology. The first product has been selected and development efforts are underway.
Under the agreement, target APIs (Active Pharmaceutical Ingredients) will be formulated using the proprietary MedinCell BEPO™ technology platform. BEPO may allow less frequent drug administration and potentially improved patient tolerability, which may reduce both direct and indirect drug costs.

Click here to view the full press release.